Lv0
0 积分 2026-04-28 加入
Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy
4个月前
已完结
Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy
4个月前
已完结
Targeting the alternative complement pathway by iptacopan abrogates C3 and strongly reduces C5b-9 deposition within glomeruli in IgA nephropathy recurrence after kidney transplantation
4个月前
已完结
A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy
4个月前
已完结
Iptacopan in IgA Nephropathy — Final 24-Month Data
4个月前
已完结
皖公网安备34019202002308
